drugset / Trial / NCT01617941
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention
RandomizedParallel-groupDouble-blindTreatment
Summary
It will provide a first evaluation of efficacy, safety and tolerability of BGG492 in patients with non-chronic migraine having more than 3 and less than 12 migraine attacks per 4 weeks.
Timeline
- Start
- 2016-05
- Primary completion
- 2016-11
- Completion
- 2016-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | selurampanel | Small molecule | 50 mg | Oral |
| Subject | selurampanel | Small molecule | 75 mg | Oral |
Indications
No indication recorded.